Gregory Saia

Gregory Saia has extensive experience in the field of quality control and method development in the biotechnology and healthcare sectors. Gregory currently serves as the Director of Method Lifecycle Management and Strategy at 2seventy bio. Prior to this, they were an Associate Director of Method Development and Qualification at bluebird bio. Gregory has also held the position of Associate Director of Quality Control at Clearpath Vaccines Company and Nosocomial Vaccine Corporation, where they led analytical activities supporting vaccine testing and clinical trial manufacturing. Earlier in their career, they were an Associate Director of Quality Control at MassBiologics, overseeing testing for vaccine and gene therapy products, and they held various roles as a QC Scientist. Gregory's expertise and experience in quality control and method development have made him a valuable asset in their roles throughout their career.

Gregory Saia holds a Ph.D. in Cell, Molecular, and Developmental Biology from Tufts University School of Medicine. Prior to that, they obtained a Bachelor of Science degree from Stonehill College. Their major was Biology, and they also pursued a minor in Business Administration. The specific start and end years for their education are not provided.